ZUG, Switzerland, April 14, 2016 /PRNewswire/ -- A recent study conducted by Spherix Global Insights found that the use of oral DMTs significantly increase at the expense of the platform injectables (Biogen's Avonex and Plegridy, Bayer's Betaseron/Betaferon, Novartis' Extavia, Serono's Rebif, Teva's Copaxone, and Momenta's Glatopa) when MS patients are switched away from their first-line therapy.
According to the RealWorld Dynamix™ DMT Switching in Multiple Sclerosis report, nearly 50% of the MS patients receiving DMT treatment have been switched, at least once, to another therapy. Switching is most commonly due to the lack of success of previous agents in reducing the number of relapses, controlling disability accumulation and slowing the progression of the disease.
"With MS diagnosis occurring earlier in the disease course and multiple DMTs now available, patients can move through several switches until finding the agent that best manages their disease," said Ines Troconis Merolli, Spherix Global Insights' Neurology Franchise Head. "Our brand analysis found that when deciding which DMT to switch to, a different MOA and the comfort level with the drugs are the top two considerations in the neurologists' mind. With switches to oral DMTs, patient request also plays a significant role in brand choice."
The deep-dive into the DMT switch dynamics in USA and Europe also reveals a positive outlook for Roche's ocrelizumab. Most neurologists participating in the study confirmed the need for new therapies to treat MS. There is a fairly high awareness of ocrelizumab already and neurologists identified many of the audited patients as potential candidates for this new agent once approved.
About Spherix Global Insights
Spherix Global Insights is a newly established business intelligence and market research company headquartered in Zug, Switzerland with US offices in Cambridge, MA. We specialize in renal, autoimmune, neurologic and rare disease markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/new-study-by-spherix-global-insights-indicates-high-therapy-switching-rates-for-multiple-sclerosis-patients-in-the-us-and-eu-benefitting-biogens-tecfidera-novartis-gilenya-and-sanofis-aubagio-300251625.html
SOURCE Spherix Global Insights